Dimerix

Dimerix Capital Expenditures

The Capital Expenditures (CapEx) of Dimerix (DXB.AX) as of Oct 11, 2026 is -4,983.00 AUD. In the previous year, Capital Expenditures (CapEx) was -21,006.00 AUD — a change of -76.28% (higher).

Capital Expenditures

-4,983.00AUD

YoY

-76.28%

Last updated:

Capital Expenditures (CapEx) of Dimerix is 2026 -4,983.00 AUD. Capital Expenditures (CapEx) of Dimerix was 2025 -21,006.00 AUD. It decreases by -76.28% higher compared to the previous year.

The Dimerix Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2019
-6,906.00 AUD
Jan 1, 2020
-9,572.00 AUD
Jan 1, 2021
-9,572.00 AUD
Jan 1, 2022
-10,614.00 AUD
Jan 1, 2023
-2,299.00 AUD
Jan 1, 2024
-15,798.00 AUD
Jan 1, 2025
-21,006.00 AUD
Jan 1, 2026
-4,983.00 AUD
The Dimerix Capital Expenditures history
YEARCapital ExpendituresYoY
-4,983.00AUD-76.28%
-21,006.00AUD+32.97%
-15,798.00AUD+587.17%
-2,299.00AUD-78.34%
-10,614.00AUD+10.89%
-9,572.00AUD0.00%
-9,572.00AUD+38.60%
-6,906.00AUD+94.92%
-3,543.00AUD+37.27%
-2,581.00AUD+30.09%
-1,984.00AUD-66.27%
-5,882.00AUD+196.47%
-1,984.00AUD—
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Capital Expenditures (CapEx) of Dimerix is -4,983.00 AUD in 2026.

Capital Expenditures (CapEx) of Dimerix changed from -21,006.00 AUD to -4,983.00 AUD, representing a -76.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Dimerix since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Dimerix historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Dimerix

All Key Metrics — Dimerix